C ontemporary management strategies of acute ST-segment-elevation myocardial infarction (STEMI) are based on the pioneering early angiographic studies of DeWood and colleagues, 1 who demonstrated an occluded coronary artery in almost 90% of these patients. Accordingly, the 'open artery' management strategy was used, initially with the use of thrombolytic therapy and subsequently with percutaneous coronary interventions. In contrast, early angiography in patients with non-ST-segment-elevation myocardial infarction (NSTEMI) showed an occluded vessel in fewer than a third of these patients, 2 so that strategies focusing on maintaining arterial patency were developed. However, both of these acute myocardial infarction (MI) angiographic studies 1,2 demonstrated the presence of significant obstructive coronary artery disease in >97% of these MI patients, thus underscoring the importance of obstructive coronary atherosclerotic disease in this condition.
have no evidence of obstructive coronary artery disease. 3 These patients with MI with nonobstructive coronary arteries (MINOCA) 4 represent a conundrum because the underlying cause of their MI is not immediately apparent. Furthermore, whether they have similar clinical features and outcomes as patients with MI with obstructive coronary artery disease (MI-CAD) is unclear. Ascertaining whether MINOCA is a distinct clinical entity with specific clinical features, outcomes, and pathophysiological mechanisms is paramount to determining the appropriate management strategy for these patients, yet to date there is no systematic review of the published literature concerning these patients. Furthermore, given the limited investigation of these patients, it is not surprising that there are no professional guidelines on the management of MINOCA.
Accordingly, the primary objectives of this systematic review are to detail the clinical attributes of these patients by systematically evaluating the published literature in regards to (1) the prevalence, clinical features, and 12-month prognosis of MINOCA patients, and (2) the major underlying pathophysiological mechanisms responsible for this disorder.
Methods
This study used a comprehensive structured systematic approach that included a methodical literature search, well-defined inclusion criteria for MINOCA, extraction of available raw data, and pooling of the data to determine the frequency of each of the predetermined study end points.
Published Literature Search
An unrestricted literature search was conducted using PubMed and Embase. The search terms in each of these databases and the subsequent evaluation process are summarized in Figure 1 . In brief, searches were conducted in both databases focusing on the terms 'myocardial infarction,' 'nonobstructive,' and 'angiography.' Only original human clinical research studies published in English were considered. However, the references in recent key review articles were also crosschecked with the database searches to ensure a comprehensive source of original papers. A search of the Cochrane database revealed no relevant systematic reviews on this topic.
Systematic Assessment of the Available Literature
Of the original human MI research studies (1033 publications) between 1966 and 2013 (inclusive), reference to nonobstructive coronary artery disease was evident in 237 publications (Figure 1 ). These articles were reviewed for the following prespecified inclusion and exclusion criteria by 2 of the investigators (S.P., R.T.).
Inclusion Criteria
For consideration in this meta-analysis, it was essential for the following criteria to be documented in the protocol of the published study:
1. Evidence of an MI 5 as defined by (1) significant elevation of a cardiac biomarker and (2) at least 2 of the following -ischemic symptoms, new ST/T changes, or new left bundle-branch block. 2. Qualitative coronary angiography findings to allow determination of the presence/absence of obstructive coronary artery disease.
MINOCA was defined as the presence of an MI (as per the above criteria) in the absence of obstructive coronary artery disease (ie, no epicardial vessel with a stenosis ≥50% on angiography). Those MI patients with significant obstructive coronary artery disease (at least 1 stenosis ≥50%) were designated as MI-CAD. The decision to use a <50% lesion threshold to delineate nonobstructive CAD from the obstructive CAD is based on the following rationale: (1) well established criteria in clinical guidelines, 6 accordingly (2) it is the most frequently used definition in published angiographic studies, (3) considering the limitations of angiography, the presence of angiographic smooth vessels does not exclude the presence of significant atherosclerosis, (4) attention should be focused on why myocardial infarction/injury has occurred in the absence of a functionally obstructive lesion, and (5) the more inclusive definition allows future prognostic studies to determine whether there is clinical utility in delineating those with angiographically smooth vessels from those with minor CAD.
Exclusion Criteria
Publications were excluded from further consideration if 1. coronary angiography was not performed in the context of an MI admission, 2. Tako-tsubo cardiomyopathy or myocarditis were the primary focus of the article, 3. there was no original data or the data were reproduced from a former study, and 4. isolated case report format.
Using these inclusion and exclusion criteria, 152 original MI publications had sufficient data to clearly identify those patients with MINOCA. Further analysis was dependent on the specific objectives of this study, namely (1) determining the clinical (primary objective) or (2) pathophysiologic (secondary objective) attributes of MINOCA ( Figure 1 ). The studies used in the analyses are listed in Table I in the online-only Data Supplement.
Because the primary objective requires a representative sample to quantitatively assess the clinical attributes of MINOCA, only publications that recruited (1) at least 100 patients with MI, and (2) consecutive MI patients, were included in the analysis. The specific definitions used in these studies for the various cardiovascular risk factors are listed in Table II in the online-only Data  Supplement. For the second objective, original studies fulfilling the above inclusion/exclusion criteria were included if they performed systematic diagnostic evaluations on a group of MINOCA patients with the intention of exploring the underlying pathophysiologic mechanism/s responsible for the MI. These included myocardial imaging studies such as cardiac magnetic resonance (CMR) imaging and functional studies such as provocative spasm testing and thrombophilia screening ( Figure 1 ). For consistency, the total frequency of each abnormal pathophysiologic investigation was documented although it is acknowledged that the findings may be time-dependent. Accordingly, the results of early investigations (ie, within 6 weeks of MI) are also described.
Data Extraction and Analysis
The end points evaluated in the primary objective included (1) prevalence of MINOCA, (2) clinical features including age, sex, MI type (STEMI or NSTEMI), cardiovascular risk factors, and (3) prognosis (including in-hospital and 12-month all-cause mortality). Data for these end points were pooled and analyzed using random effects meta-analysis models. 7 This conservative approach assumes that individual studies are estimating different treatment effects. Heterogeneity in the study estimates were assessed using I 2 statistics 8 with larger values indicating increasing heterogeneity between studies. In addition, for studies including both MINOCA and MI-CAD patients, the summary odds ratios (ORs) or mean difference and exact 95% confidence intervals (95% CI) were calculated. Data from the pathophysiologic mechanistic publications was more limited so that qualitative assessment could only be undertaken. This involved pooling of frequency data from studies with similar end points. All analyses were performed using STATA (version 12, College Station, Tex.) by guest on April 15, 2017 http://circ.ahajournals.org/
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Results
From the 152 MINOCA publications identified on PubMed and Embase, we embarked on (1) quantitative assessment of 28 studies to evaluate the clinical attributes of the condition and (2) qualitative evaluation of 46 studies that focused on its pathophysiologic attributes ( Figure 1 and Table I in the onlineonly Data Supplement). These clinical and pathophysiologic attributes of MINOCA are detailed below.
Prevalence
The prevalence of MINOCA was determined from 27 large clinical trials/registries involving 176 502 consecutive MI patients who had coronary angiography performed. These studies reported a prevalence of MINOCA ranging from 1% to 14% with an overall prevalence calculated at 6% (95% CI, 5%-7%), based on random effects analysis ( Figure 2 ). The I 2 statistic was estimated to be 99%.
Clinical Features
Sex
In the 15 publications reporting gender (n=11 334), pooled analyses revealed that only 40% (95% CI, 33%-46%) of MINOCA patients were women. However pooled analysis of 10 studies that recruited both MINOCA (n=5322) and MI-CAD (n=70 253) patients, revealed an over-representation of women with MINOCA (43%; 95% CI, 35%-51%) relative to that observed with MI-CAD (24%; 95% CI, 19%-30%; Table 1 ). Age Sufficient data were available in 13 studies (n=9986) to determine the pooled mean age of MINOCA patients. This was calculated to be ≈55 years (95% CI, 51-59 years) with no significant heterogeneity between studies as estimated by the I 2 statistic. In 6 publications, data on age were available for both MINOCA (n=3927) and MI-CAD (n=48 082) patients, with the respective pooled mean ages between 58.8 (95% CI, 51.6-66.1 years) and 61.2 years (95% CI, 52.2-70.4 years). Analysis of these comparative studies confirmed that patients with MINOCA were younger than those with MI-CAD. This analysis may have underscored this difference because the 6 studies included in this comparison recruited MINOCA patients at the upper age spectrum of the overall MINOCA cohort ( Table 1) .
Cardiovascular Risk Factors
By evaluating comparative studies that included both MINOCA and MI-CAD patients, the relative frequencies of cardiovascular risk factors were determined. These are summarized in Table 1 along with the cardiovascular risk profile from all available MINOCA studies. Results reported within this section will be confined to the comparative studies. Compared with MI-CAD patients, those with MINOCA were less likely to have hyperlipidemia (32% [95% CI, 30%-59%] versus 21% [95% CI, 6%-35%], respectively; OR, 0.63; P<0.001). However, it is noteworthy that the prevalence of hyperlipidemia among MINOCA patients in these comparative studies was considerably lower than that observed for the overall MINOCA cohort (33%; 95% CI, 25%-41%). Other cardiovascular risk factors including hypertension, diabetes mellitus, smoking, and family history of premature coronary artery disease were similar between the groups (Table 1) .
Infarct ECG Findings
Ten studies (n=1998) documented the prevalence of an acute STEMI presentation among MINOCA patients. Pooled analysis revealed that 33% (95% CI, 22%-44%) presented with features of STEMI ( Figure 3 ). Accordingly, approximately two-thirds of patients were categorized with NSTEMI.
Angiographic Findings
By definition, MINOCA patients have <50% lesions on angiography. The relative frequency of smooth vessels (ie, no lesions visible on angiography) compared with minor irregularities on angiography was assessed in 5 clinical trials with 1046 MINOCA patients ( Figure I in the online-only Data Supplement). Among the MINOCA patients, the prevalence of smooth vessels on angiography was 51% (95% CI, 39%-61%). Importantly, the I 2 test confirmed the presence of significant heterogeneity among these studies.
Prognosis
Studies assessing prognosis in patients with MINOCA were considerably heterogeneous in their follow-up period, and few reported the prevalence of cardiac mortality or reinfarction. Overall, 8 studies reported all-cause mortality in patients with MINOCA, including in-hospital (5 studies, n=9564), and 12 months (4 studies, n=1924) after MI. Pooled meta-analysis of these studies revealed an all-cause in-hospital and 12-month mortality of 0.9% (95% CI, 0.5%-1.3%) and 4.7% (95% CI, 2.6%-6.9%), respectively. In 6 of these 8 studies, all-cause mortality was assessed in both MINOCA and MI-CAD patients, thereby allowing comparisons of the relative mortality between these forms of MI. As shown in Table 2 , although the in-hospital mortality and 12-month mortality were lower in MINOCA patients, the findings remain of concern considering the limited clinical attention received by these patients.
Potential Pathophysiological Mechanisms
Of the 81 original publications investigating the potential mechanisms responsible for MI in MINOCA patients, 46 used three distinct approaches, including (1) assessment of structural myocardial dysfunction with CMR imaging (26 publications), (2) provocative coronary artery spasm testing (15 publications), and (3) thrombophilia screening (8 publications, including 3 of the spasm studies). The remaining 35 publications used more heterogeneous approaches investigating isolated aspects of MINOCA and were therefore not conducive to pooled analysis.
Structural Myocardial Dysfunction
Pooled analyses of the 26 CMR imaging publications involving MINOCA patients revealed features consistent with a subendocardial infarct on delayed hyperenhancement in only 24% of 1801 MINOCA patients studied. The most common finding in the CMR imaging studies was myocarditis, with 33% of the 1676 MINOCA patients having features of this condition. Other myocardial abnormalities reported in the MINOCA CMR imaging studies included Tako-tsubo cardiomyopathy (18% of 1529 patients), hypertrophic cardiomyopathy (3% of 1074 patients), dilated cardiomyopathy (2% of 625 patients), and other causes (7% of 760 patients) such as pericarditis and amyloidosis. Importantly, 26% of 1592 MINOCA patients undergoing contrast CMR imaging did not have detectable myocardial abnormalities. Of the above investigations, 16 CMR studies were undertaken within 6 weeks of the MI (Table III in the online-only Data Supplement). These reported similar frequencies in abnormal CMR findings, including subendocardial infarct (24%), myocarditis (38%), Tako-tsubo cardiomyopathy (16%), and no significant abnormality (21%).
Coronary Artery Spasm
Provocative spasm testing was undertaken in 14 studies involving MINOCA patients (Table 3 ). Of the 402 MINOCA patients in the pooled dataset, 28% had inducible spasm. In 8 studies (n=298), provocative testing was performed within 6 weeks of an MI and 28% had inducible spasm. In 4 studies (n=90), provocation testing was undertaken in MINOCA patients with an old myocardial infarct (ie, MI≥6 weeks) and spasm was provoked in 34% of patients (Table 3) .
Thrombophilia Disorders
As summarized in Table 4 , 8 publications examined the presence of inherited thrombotic disorders in patients with MINOCA, with most undertaken in the early postinfarction period. Pooled analyses revealed the following abnormalities within the coagulation pathway: activated protein C resistance or factor V Leiden in 12% of 344 patients, protein C/protein S deficiency in 3% of 189 patients, and factor XII deficiency in 3% of 163 patients. Overall, 14% of the 378 MINOCA patients who underwent thrombophilia screening had evidence of an inherited thrombotic disorder.
Discussion
This detailed systematic review provides the first comprehensive overview of patients with MINOCA. It demonstrates that MINOCA has (1) a 6% prevalence of all MI presentations, (2) no diagnostic distinguishing clinical presentation features compared with MI-CAD, (3) a better 12-month all-cause mortality compared with MI-CAD, although its prognosis should be considered as guarded, and (4) structural dysfunction, coronary spasm, and thrombotic disorders as some potential underlying causes. Given that MINOCA has similar features to MI-CAD, a guarded prognosis, and multiple potential causes, it should be considered a working diagnosis that requires further evaluation of the potential underlying causes because these may have important clinical implications.
MINOCA Patients Do Not Have a Distinguishing Clinical Presentation
Patients with MINOCA may present with STEMI or NSTEMI, with two-thirds presenting as the latter. Compared with MI-CAD patients, those with MINOCA tend to be younger, predominantly male (although women are overrepresented relative to those with MI-CAD, 40% versus 25%, respectively) with significant cardiovascular risk factors, although less often have hyperlipidemia (Table 1) . Thus although there are statistical differences in the clinical profile of patients with MINOCA, there are no clinically distinguishing characteristics or risk factors that can easily delineate these patients from those with MI-CAD based on a systemic review of the literature. Specific future studies examining details of the clinical history may be more discerning. Once coronary angiography is performed and defines the MINOCA patients, completely smooth (ie, normal) coronary arteries are observed in only half of the patients, with many having minor irregularities thereby justifying the designation MINOCA. The clinical importance of delineating MINOCA patients with angiographically smooth coronary arteries from those with only mild irregularities needs to be clarified in future prognostic studies. The only published MINOCA study that has undertaken this comparison examined 12-month allcause mortality and reported poorer outcomes in those with smooth coronaries, however sample size was small (24 deaths in total). 9 If future studies demonstrate different outcomes in these angiographic subgroups, then it will be justifiable to clinically delineate them.
MINOCA Patients Have a Guarded Prognosis
Patients with MINOCA have a significantly reduced all-cause mortality compared with those with MI-CAD, including a 63% lower in-hospital mortality and 41% lower 12-month mortality ( Table 2) .
Although these findings may be reassuring, the 4.7% (95% CI, 2.6%-6.9%) 12-month all-cause mortality for patients with MINOCA is of concern when compared with other published prognostic studies. Firstly, the Korean MI Registry 10 evaluated 12-month all-cause mortality in 8510 consecutive MI patients, reporting a 3.1% mortality in those with MINOCA, 3.2% in those with single or double vessel coronary artery disease, and 6.5% in those with triple vessel disease or a significant left main coronary artery stenosis. Secondly, patients with stable chest pain (ie, no previous MI) and normal smooth coronaries on angiography have a 0.2% annual all-cause mortality, whereas those with only minor luminal irregularities have a 0.3% annual all-cause mortality. 11 Accordingly, MINOCA patients appear to have a poorer prognosis than those with stable chest pain and nonobstructive coronary artery disease, and more akin to those with an MI and single/double vessel coronary artery disease. Thus their prognosis should be considered somewhat guarded despite being better than those with MI-CAD.
MINOCA -A Heterogeneous Working Diagnosis With Some Treatable Causes
Similar to the diagnosis of heart failure, MINOCA should not be considered as a specific diagnosis but a heterogeneous working diagnosis that requires further evaluation to elucidate potential underlying causes. Identifying the cause of MINOCA is important because it may have prognostic implications (eg, identification of a cardiomyopathy), but even more importantly it may require institution of specific therapies to treat the underlying cause. Important MINOCArelated diagnoses that may warrant specific targeted therapies include structural myocardial dysfunction (such as cardiomyopathies), coronary spasm, and thrombophilia disorders. These are further discussed below.
Structural Myocardial Dysfunction
The detection of structural heart disease with CMR imaging in patients with MINOCA syndrome can reveal cardiomyopathies such as Tako-tsubo, hypertrophic, or dilated cardiomyopathy ( Figure 4 ). Although Tako-tsubo cardiomyopathy is an important diagnosis considering its prognostic implications, currently there are no specific therapies for this condition. In contrast, hypertrophic and dilated cardiomyopathy (although seldom detected in MINOCA patients) have important management strategies/therapies that can influence patient outcomes. Accordingly, detection of these treatable conditions further justifies the routine use of CMR imaging in patients with MINOCA because it is the optimal diagnostic imaging modality for delineating cardiac structural disorders in this condition. Myocarditis is an important cause of MINOCA that is optimally diagnosed by CMR imaging. It accounts for approximately a third of MINOCA cases and provides a definitive diagnosis that may have prognostic implications, although generally it requires only conservative management.
Another important MINOCA subgroup detected by CMR imaging are those with a subendocardial infarct pattern on delayed hyper-enhancement images. The infarct may arise from transient occlusive coronary spasm or thrombosis. 12
Coronary Spasm
More than a quarter of patients with MINOCA undergoing provocative spasm testing have inducible spasm. Unfortunately there are no suitable studies directly comparing provocative spasm testing between MINOCA and MI-CAD patients, although several have reported inducible spasm in 20% to 80% of MI-CAD patients. 13, 14 Thus the relative contribution of coronary spasm to the pathophysiology of MINOCA requires further investigation.
There are several interesting observations in relation to provocative spasm testing findings in patients with MINOCA. First, there is no time-dependence for inducible spasm among MINOCA patients (Table 3) , whereas MI-CAD patients with a recent (<6 weeks) infarct are more likely to have inducible spasm than those with an old (>6 weeks) infarct. Whether the persistent inducible spasm in MINOCA patients reflects an underlying vasospastic predisposition is open to speculation. Second, there appears to be an ethnic predisposition to coronary spasm in patients with a recent myocardial infarct, 14 particularly among Japanese patients. 15 Fukai et al 16 from Japan reported an 81% prevalence of inducible spasm in patients with MINOCA, whereas studies from Europe 17-20 and the United States 21, 22 have a pooled prevalence of only 14%. Interestingly, other Asian-based studies 23, 24 also report a high prevalence of inducible spasm (Table 3 ). Finally, cocaine may induce coronary spasm and should be considered as a potential cause of MINOCA, however a recent large registry reported that cocaine use was associated with only 0.9% of MI cases. 25 The above findings relating to coronary spasm in MINOCA are exploratory and require further investigation because the data are heterogeneous with the studies differing in their study design, provocation stimulus, and coronary spasm definition. In particular, ergonovine provocation is less often used because it is no longer available in some countries and acetylcholine has become the preferred provocation stimulus. Despite these study differences, the importance of coronary spasm as a potential cause of MINOCA must not be overlooked as it appears to occur frequently and the use of calcium channel blockers is an independent determinant of survival in patients with coronary spasm. 26 
Thrombophilia Disorders
As summarized in Table 4 , genetic thrombophilia disorders have been observed in MINOCA. Factor V Leiden is a single point mutation with a prevalence of 3% to 7% in Western populations 27 but was observed in 12% of MINOCA patients. Furthermore, comparative studies with MI-CAD patients also report a higher prevalence in MINOCA (Mansourati et al 28 27 yet occur in 2.6% of MINOCA patients and similarly those with MI-CAD. 30 These associations with the genetic thrombophilia disorders are based on small studies and require confirmation with larger multicenter prospective studies. Furthermore, investigation of acquired thrombophilia disorders should be considered because these may also occur in the context of acute MI and could exacerbate the genetic disorders. Irrespective of the prevalence of these thrombophilia disorders in MINOCA, their detection may influence subsequent management thereby justifying their routine evaluation in patients with MINOCA.
Limitations
The results from this structured systematic review should be interpreted in the context of several potential limitations. First, the analysis is dependent on the available published data and is thus limited by publication bias, patient selection bias, suboptimal definitions for cardiovascular risk factors, retrospective analyses, and applicability of historical publications to contemporary practice. Second, there is significant heterogeneity between the studies included in the meta-analysis although the random effects model approach used in this study is less influenced by this pitfall. Third, the second objective, which focused on pathophysiological studies, did not lend itself to quantitative meta-analysis but a qualitative evaluation of published data. This was necessary because there were differences in patient recruitment, methods of investigation, and definitions of a positive result, for each of the respective studies involving CMR imaging, provocative spasm testing, and genetic thrombophilia disorders.
Conclusions
This systematic review provides an important reference point for further research and development of MINOCA. It demonstrates that the condition is not uncommon, has no delineating clinical presentation, a guarded 12-month prognosis, and multiple potential causes with some amenable to specific therapies. Despite this, there are no guidelines regarding the management of these patients and limited insights into the contemporary management undertaken (if any) in affected patients. Based on the findings of this systematic review, we would propose that MINOCA be considered a working diagnosis that requires routine evaluation for treatable underlying causes. This may include CMR imaging, provocative spasm testing, and thrombophilia assessment. Further research is required to define the optimal therapy in MINOCA patients who do not have an identifiable underlying cause. These strategies may potentially improve the guarded prognosis in these patients.
CLINICAL PERSPECTIvE
This article systematically summarizes the published literature concerning patients with myocardial infarction with nonobstructive coronary arteries. These patients account for 6% of all those experiencing an acute myocardial infarct. Although they have a similar prevalence for many risk factors to those with myocardial infarction associated with obstructive coronary artery disease, in comparison they tend to be younger, more often female, and less likely to have hyperlipidemia. Moreover, although their prognosis is better than those with obstructive coronary artery disease, it remains guarded with an all-cause mortality of 4.7% (95% confidence interval, 2.6%-6.9%) at 12 months. The key clinical practice implication from this study is that myocardial infarction with nonobstructive coronary arteries should be considered as a working diagnosis that necessitates further investigation for an underlying cause (ie, similar to that required for a heart failure diagnosis). Important causes include myocarditis, Tako-tsubo cardiomyopathy, vasospastic angina, and hereditary thrombophilia disorders, all of which require different management strategies. Cardiac magnetic resonance imaging is a useful initial investigation to delineate some of these causes. Assessment for coronary artery spasm and thrombophilia disorders should also be considered. The importance of identifying these causes resides with the potential to use effective therapies that otherwise may not have been considered and that may impact on prognosis (eg, calcium channel blockers for coronary spasm). Accordingly, there is the potential to reduce the guarded prognosis in these patients. The publications listed below are those selected to evaluate objective A (clinical characteristics) and B (pathophysiological mechanism) in this systematic review, as summarised in Figure- Table 1&2 A- 14 Larsen AI, Galbraith PD, Ghali WA, Norris CM, Graham MM, Knudtson ML. 
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